XenoSure Biologic Patch e1P6Recalls & reported problems
Lemaitre Vascular, Inc. · XenoSure Biologic Patch, 1cm x 6cm · Class 2 · Implant
- Adverse event reports
- 10
- Deaths reported
- 0
- Injuries reported
- 9
- Recalls naming it
- 0
Summary
The FDA's MAUDE database contains 10 adverse event reports that list this exact device (DI 00840663106288), received between Dec 8, 2017 and Mar 28, 2025 — classified as 9 injuries, 1 malfunction.
The most frequently reported specific device problem is “Patient Device Interaction Problem” (5 reports).
Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. How this data works · Data updated Oct 13, 2026.
Reports received per month
Most reported problems
Device problems
- Patient Device Interaction Problem5
- Adverse Event Without Identified Device or Use Problem1
- Contamination /Decontamination Problem1
- Delamination1
- Insufficient Device Problem Information1
- Material Integrity Problem1
Patient problems
- Thrombosis3
- Bacterial Infection2
- Hematoma1
- Medical device site infection1
- No Information1
- Stenosis1
- Thrombosis/Thrombus1
- Unspecified Infection1
Recent adverse event reports
The 10 most recent of 10 reports, in the reporter's own words as published by the FDA.
InjuryMar 28, 2025Patient Device Interaction Problem; Patient Device Interaction Problem
IT WAS REPORTED THAT A PATIENT HAD A CAROTID ENDARTERECTOMY WITH PATCH ANGIOPLASTY USING THE XENOSURE PATCH. THE INITIAL SURGERY WAS PERFORMED ON (B)(6) 2025. THE PATIENT CAME BACK TO THE HOSPITAL WITH AN INFECTION ON (B)(6) 2025. ON (B)(6) 2025 THE INFECTION WAS REMOVED AND THE INTERVENTION WAS REPAIRED WITH THE PATIENT'S GREAT SAPHENOUS VEIN. THE VASCULAR COORDINATOR DID NOT KNOW THE EXACT CAUSE OF THE INFECTION. ADDITIONAL INFORMATION RECEIVED STATES THE CULTURE GREW STREP ANGINOUSUS.
Patient problems: Medical device site infection
MAUDE report 21718898 ↗InjuryMay 15, 2024Patient Device Interaction Problem; Patient Device Interaction Problem
IT WAS REPORTED THAT POST CAROTID ENDARTERECTOMY WITH XENOSURE PATCH ANGIOPLASTY, THE PATIENT CAME BACK WITH A STAPHYLOCOCCUS INFECTION ORIGINATING FROM THE PATCH SITE. THE INFECTED PATCH WAS REMOVED AND THE PATIENT'S CAROTID WAS REPAIRED WITH APPLICATION OF NATIVE GSV GRAFT.
Patient problems: Bacterial Infection
MAUDE report 19322843 ↗InjuryJun 24, 2022Contamination /Decontamination Problem; Contamination /Decontamination Problem
PATIENT HAD A CAROTID ENDARTERECTOMY WITH PATCH DONE ON 2020. SHE WAS PRESENTED IN 2022 WITH AN INFECTED PATCH REQUIRING SURGICAL INTERVENTION. FDA NOTIFIED THIS INCIDENT TO LEMAITRE ON 5/27/2022. FDA PROVIDED LEMAITRE WITH A COPY OF VOLUNTARY MEDWATCH REPORT# MW5109514.
Patient problems: Unspecified Infection
MAUDE report 14799415 ↗InjuryApr 25, 2022Adverse Event Without Identified Device or Use Problem; Adverse Event Without Identified Device or Use Problem
PATIENT HAD A CAROTID ENDARTERECTOMY WITH PATCH DONE ON (B)(6) 2020. SHE PRESENTED IN (B)(6) 2022 WITH AN INFECTION THAT REQUIRED SURGICAL INTERVENTION. CULTURE OF EXPLANTED PATCH SHOWED INFECTION.
Patient problems: Bacterial Infection
MAUDE report 14197397 ↗InjuryNov 25, 2020Insufficient Device Problem Information
ON (B)(6) 2020, SURGEON INQUIRED SALES REP. IF HE HAS EVER SEEN OR IF THERE IS ANY DOCUMENTATION OF THROMBOSIS OF FEMORAL ARTERY AFTER PATCH PLACEMENT AND ENDARTERECTOMY.
Patient problems: Stenosis; Thrombosis/Thrombus
MAUDE report 10899816 ↗InjuryFeb 21, 2019Patient Device Interaction Problem; Patient Device Interaction Problem
DURING A ROUTINE SALES CALL, SURGEON MENTIONED A SERIES OF 3 CAROTID ENTARTERECTOMY PATIENTS WHO WERE READMITTED DUE TO BLOOD CLOTS. THIS IS REPORT 2 OF 3 OF THAT SERIES.
Patient problems: Thrombosis
MAUDE report 8357852 ↗InjuryFeb 21, 2019Patient Device Interaction Problem; Patient Device Interaction Problem
DURING A ROUTINE SALES CALL, SURGEON MENTIONED A SERIES OF 3 CAROTID ENDARTERECTOMY. PATIENTS WHO WERE READMITTED DUE TO BLOOD CLOTS. THIS IS REPORT 3 OF 3 OF THAT SERIES.
Patient problems: Thrombosis
MAUDE report 8357850 ↗InjuryFeb 21, 2019Patient Device Interaction Problem; Patient Device Interaction Problem
DURING A ROUTINE SALES CALL, SURGEON MENTIONED A SERIES OF 3 CAROTID ENDARTERECTOMY PATIENTS WHO WERE READMITTED DUE TO BLOOD CLOTS. THIS IS REPORT 1 OF 3 OF THAT SERIES.
Patient problems: Thrombosis
MAUDE report 8357848 ↗InjuryDec 1, 2018Material Integrity Problem; Material Integrity Problem
ON (B)(6) 2018, PATIENT UNDERWENT RIGHT CAROTID ENDARTERECTOMY FOLLOWED BY AN ANGIOPLASTY CLOSURE OF THE CAROTID ARTERY USING A XENOSURE BIOLOGIC PATCH CATALOG# E1P6 LOT# XBU3083. ON (B)(6) 2018, THE PATIENT RETURNED TO THE HOSPITAL WITH A MODERATE SIZED LOCALIZED HEMATOMA IN THE SUPERIOR ASPECT OF THE RIGHT NECK INCISION. COMPUTED TOMOGRAPHY ANGIOGRAPHY (CTA) OF THE NECK PERFORMED AT THE FACILITY DIAGNOSED A PSEUDOANEURYSM WITH AN ACTIVE BLEEDING OF THE CAROTID ARTERY AT THE IMPLANTED PATCH SITE .
Patient problems: Hematoma
MAUDE report 8122025 ↗MalfunctionDec 8, 2017Delamination; Delamination
XENOSURE PATCH FRAYED AFTER BEING SUTURED IN THE PATIENT. SO, THE PATCH WAS EXPLANTED AND REPLACED WITH AN ANOTHER PATCH.
Patient problems: No Information
MAUDE report 7100932 ↗
Other Mesh, Surgical devices
- MEDPOR TITAN 81032Stryker Leibinger GmbH & Co. KG · Mesh, surgical1 recall1 report
- Peri-Guard PC1016NSynovis Life Technologies, Inc. · Mesh, surgical1 recall1 report
- Supple Peri-Guard SPG0404Synovis Life Technologies, Inc. · Mesh, surgical1 recall0 reports
- SurgiMend® 606-403-001Tei Biosciences Inc. · Mesh, surgical1 recall0 reports
- SurgiMend® 606-300-006Tei Biosciences Inc. · Mesh, surgical1 recall0 reports
- SurgiMend® 606-300-019Tei Biosciences Inc. · Mesh, surgical1 recall0 reports
- SurgiMend® 606-001-009Tei Biosciences Inc. · Mesh, surgical1 recall0 reports
- SurgiMend® 606-004-105Tei Biosciences Inc. · Mesh, surgical1 recall0 reports
Sources: FDA GUDID, MAUDE and Medical Device Recalls via openFDA. openFDA data is not validated for clinical or regulatory use.